410 related articles for article (PubMed ID: 26338470)
1. Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.
Karp Leaf R; Cho HJ; Avigan D
Curr Hematol Malig Rep; 2015 Dec; 10(4):395-404. PubMed ID: 26338470
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
4. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care.
Koehne G; Giralt S
Curr Opin Oncol; 2012 Nov; 24(6):720-6. PubMed ID: 22960558
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.
Festuccia M; Martino M; Ferrando F; Messina G; Moscato T; Fedele R; Boccadoro M; Giaccone L; Bruno B
Expert Opin Biol Ther; 2015 Jun; 15(6):857-72. PubMed ID: 25865214
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic haematopoietic cell transplantation for multiple myeloma: reducing transplant-related mortality while harnessing the graft-versus-myeloma effect.
Zeiser R; Finke J
Eur J Cancer; 2006 Jul; 42(11):1601-11. PubMed ID: 16759847
[TBL] [Abstract][Full Text] [Related]
8. Homing characteristics of donor T cells after experimental allogeneic bone marrow transplantation and posttransplantation therapy for multiple myeloma.
van der Voort R; Volman TJ; Verweij V; Linssen PC; Maas F; Hebeda KM; Dolstra H
Biol Blood Marrow Transplant; 2013 Mar; 19(3):378-86. PubMed ID: 23266741
[TBL] [Abstract][Full Text] [Related]
9. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
[TBL] [Abstract][Full Text] [Related]
10. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
Kyle RA
Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780
[TBL] [Abstract][Full Text] [Related]
11. Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma.
Lendvai N; Cohen AD; Cho HJ
Bone Marrow Transplant; 2015 Jun; 50(6):770-80. PubMed ID: 25751647
[TBL] [Abstract][Full Text] [Related]
12. Immune therapy in multiple myeloma.
Luptakova K; Avigan D
Clin Adv Hematol Oncol; 2015 Nov; 13(11):767-75. PubMed ID: 27058703
[TBL] [Abstract][Full Text] [Related]
13. Strategies to improve the outcome of stem cell transplantation in multiple myeloma.
Catley L; Anderson K
Hematol J; 2004; 5(1):9-23. PubMed ID: 14745425
[TBL] [Abstract][Full Text] [Related]
14. Cellular immunotherapy for plasma cell myeloma.
Garfall AL; Vogl DT; Weiss BM; Stadtmauer EA
Bone Marrow Transplant; 2013 Nov; 48(11):1377-86. PubMed ID: 23645169
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibody-based immunotherapy for multiple myeloma.
Danylesko I; Beider K; Shimoni A; Nagler A
Immunotherapy; 2012 Sep; 4(9):919-38. PubMed ID: 23046236
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for multiple myeloma.
Rosenblatt J; Bar-Natan M; Munshi NC; Avigan DE
Expert Rev Hematol; 2014 Feb; 7(1):91-6. PubMed ID: 24417573
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint inhibition to prevent or treat relapse in allogeneic hematopoietic cell transplantation.
Soiffer RJ
Bone Marrow Transplant; 2019 Aug; 54(Suppl 2):798-802. PubMed ID: 31431704
[TBL] [Abstract][Full Text] [Related]
18. Cellular and vaccine immunotherapy for multiple myeloma.
Garfall AL; Stadtmauer EA
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):521-527. PubMed ID: 27913524
[TBL] [Abstract][Full Text] [Related]
19. A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma?
Green DJ; Bensinger WI
Curr Hematol Malig Rep; 2017 Feb; 12(1):61-67. PubMed ID: 28144893
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.
Pianko MJ; Moskowitz AJ; Lesokhin AM
Clin Cancer Res; 2018 Mar; 24(5):1002-1010. PubMed ID: 28899972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
